{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-011834","form_type":"8-K","ticker":"VVOS","cik":"0001716166","company_name":"Vivos Therapeutics, Inc.","filed_at":"2024-03-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.227676+00:00","generated_at":"2026-06-04T05:26:19.362318+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Vivos Therapeutics Reports FY2023 Revenue Decline, 27% OpEx Reduction, and FDA Clearance for Severe OSA","bullets":["Revenue for Q4 2023 was $3.2M and full year $13.8M, down from $4.0M and $16.0M in 2022, due to lower appliance revenue and VIP enrollments.","Operating expenses decreased 27% in FY2023, leading to a 43% reduction in net loss, as cost-cutting initiatives took effect.","In November 2023, Vivos received FDA 510(k) clearance for its CARE oral appliances to treat severe OSA in adults, a first for oral devices.","Signed VIP enrollment contracts increased 38% sequentially in Q4 2023 following the FDA clearance, indicating improved business momentum.","Cash and equivalents were $1.6M at year-end; a warrant exercise in February 2024 generated $4.0M in gross proceeds."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-011834","json":"https://secwatch.observer/filing/0001493152-24-011834.json","markdown":"https://secwatch.observer/filing/0001493152-24-011834.md","text":"https://secwatch.observer/filing/0001493152-24-011834.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1716166/000149315224011834/0001493152-24-011834-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1716166/000149315224011834/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T05:26:19.362318+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d415f61bdc728a1080cd2c4938f0f83da67f94bc","claim":"Vivos Therapeutics, Inc. reported financial results for fourth quarter and full year ended December 31, 2023.","evidence_excerpt":"On March 28, 2024, Vivos Therapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the fourth quarter and fiscal year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1716166/000149315224011834/0001493152-24-011834-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"fourth quarter and full year ended December 31, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}